Optimizing treatment of the partially platinum-sensitive ovarian cancer patient.

Future oncology (London, England) (2013-11-15)
Nicoletta Colombo
RESUMO

Ovarian cancer is the leading cause of gynecological cancer deaths worldwide. Despite primary treatment with platinum-containing regimens, the majority of women will experience recurrent disease and subsequent death. Recurrent ovarian cancer remains a challenge for successful management, and the choice of second-line chemotherapy is complex due to the range of different factors that need to be considered. One of the main considerations is the platinum-free interval and, specifically, the optimal treatment for patients who are partially platinum-sensitive (platinum-free interval: 6-12 months). Data from the large, multicenter, randomized OVA-301 study have shown that combined trabectedin-pegylated liposomal doxorubicin (PLD) significantly prolonged median overall survival compared with PLD alone (p = 0.0027) in 214 patients with partially platinum-sensitive advanced relapsed ovarian cancer. Furthermore, in OVA-301 patients with partially platinum-sensitive disease who received platinum therapy immediately after disease progression (n = 94), final median overall survival was improved by 9 months (p = 0.0153) in trabectedin-PLD patients compared with PLD alone. In addition to demonstrating a survival advantage, trabectedin-PLD may also allow the treatment of patients having not yet recovered from previous platinum toxicity. In summary, the data suggest the use of combined trabectedin-PLD as a second-line treatment option in patients with partially platinum-sensitive recurrent ovarian cancer, followed by a third-line platinum-containing regimen.

MATERIAIS
Número do produto
Marca
Descrição do produto

Sigma-Aldrich
Platinum, wire, diam. 0.5 mm, 99.99% trace metals basis
Sigma-Aldrich
Platinum, foil, thickness 0.025 mm, 99.9% trace metals basis
Sigma-Aldrich
Platinum, wire, diam. 0.25 mm, 99.9% trace metals basis
Sigma-Aldrich
Platinum, wire, diam. 0.5 mm, 99.9% trace metals basis
Sigma-Aldrich
Platinum, gauze, 100 mesh, 99.9% trace metals basis
Sigma-Aldrich
Platinum black, black, powder, ≤20 μm, ≥99.95% trace metals basis
Sigma-Aldrich
Platinum, wire, diam. 1.0 mm, 99.9% trace metals basis
Sigma-Aldrich
Platinum, foil, thickness 0.05 mm, 99.99% trace metals basis
Sigma-Aldrich
Platinum, powder, 99.995% trace metals basis
Sigma-Aldrich
Platinum, gauze, 52 mesh, 99.9% trace metals basis
Sigma-Aldrich
Platinum, nanopowder, <50 nm particle size (TEM)
Sigma-Aldrich
Platinum, wire, diam. 2.0 mm, 99.9% trace metals basis
Sigma-Aldrich
Platinum, wire, diam. 0.10 mm, 99.99% trace metals basis
Sigma-Aldrich
Platinum, powder, ≤10 μm, 99.9% trace metals basis
Sigma-Aldrich
Platinum, wire, diam. 0.25 mm, 99.99% trace metals basis
Sigma-Aldrich
Platinum black, fuel cell grade, ≥99.9% trace metals basis
Sigma-Aldrich
Platinum, wire, diam. 0.076 mm, ≥99.99% trace metals basis
Sigma-Aldrich
Platinum, foil, thickness 0.125-0.135 mm, 99.9% trace metals basis
Sigma-Aldrich
Platinum, foil, thickness 1.0 mm, 99.99% trace metals basis
Sigma-Aldrich
Platinum, foil, thickness 0.25 mm, 99.99% trace metals basis
Sigma-Aldrich
Platinum, nanopowder, 200 nm particle size (SEM), 99.9% (metals basis)
Sigma-Aldrich
Platinum, wire, diam. 0.25 mm, thermocouple grade
Sigma-Aldrich
Platinum, wire, diam. 0.127 mm, 99.99% trace metals basis
Sigma-Aldrich
Platinum, wire, diam. 1.0 mm, 99.99% trace metals basis
Sigma-Aldrich
Platinum, wire, diam. 0.20 mm, ≥99.99% trace metals basis
Sigma-Aldrich
Platinum, wire, diam. 0.127 mm, 99.9% trace metals basis
Sigma-Aldrich
Platinum, powder (coarse), 99.99% trace metals basis
Sigma-Aldrich
Platinum black, low bulk density, ≥99.9% trace metals basis
Platinum, wire reel, 0.1m, diameter 1.0mm, annealed, may be used as one component of a thermocouple, 99.99%
Platinum, wire reel, 1m, diameter 0.3mm, annealed, may be used as one component of a thermocouple, 99.99%

Redes sociais

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

Merck

Pesquisa. Desenvolvimento. Produção.

Somos um fornecedor global líder para o setor de ciências biológicas, com soluções e serviços para pesquisa, desenvolvimento e produção de biotecnologia, além de produção e desenvolvimento de terapias farmacológicas com medicamentos.

© 2021 Merck KGaA, Darmstadt, Alemanha e/ou suas filiais. Todos os direitos reservados.

A reprodução não autorizada de quaisquer materiais deste site é estritamente proibida.